



PROGRAMME - Sunday 18 October 2009

0800–1700	Registration (Main Foyer)	
	Hall C	Hall B
	HSANZ	ANZSBT
0900–1030	Symposium: MPD incl CML	Symposium: Transfusion Practice
	Chair - Peter Browett	Chair - Peter Flanagan
	Radek Skoda, Switzerland: (0900) <i>The Pathogenesis of Myeloproliferative Syndromes</i>	Lena Napolitano, USA: (0900) <i>Artificial Oxygen Carriers and Erythropoietin Use in Trauma Patients</i>
	Tim Hughes, SA: (0945) <i>Optimising Response in CML</i>	Dafydd Thomas, UK: (0945) <i>Intra-operative Blood Salvage</i>
1030–1100	MORNING TEA (Exhibition Hall)	
1100–1200	Symposium: BM Failure	Symposium: Transfusion Safety
	Chair - Jeff Szer	Chair – Nicole Staples
	Neal Young, USA: (1100) <i>Pathogenesis and Treatment of Bone Marrow Failure</i>	Paul Ness, USA: (1100) <i>Patient Safety and Blood Transfusion</i>
		Ken Davis, SA: (1130) <i>Pathogen Reduction by Inactivation Technologies – The New Frontier for Safeguarding Cellular Blood Products?</i>
1200–1300	Barry Firkin Oration (Hall C) Chair – Chris Ward John Fletcher, NSW: <i>Guidelines for Venous Thromboembolism Prophylaxis –Complexity, Confusion, Controversy</i>	
1300–1400	LUNCH (Exhibition Hall) ANZSBT AGM (Hall B) BMTSAA AGM (Meeting Rooms 1/2)	
1400–1530	HSANZ BMTSAA Nurses Combined Symposium: Transplantation 1 Which alternative donor to use?	Symposium: The Universal Blood Cell
	Chair - Peter Bardy	Chair – Ken Davis
	Sergio Giralt, USA: (1400) <i>Choosing The Optimal Donor - Going Beyond Siblings</i>	Martin Olsson, Sweden: (1400) <i>Towards Universal Blood Supply – Fact or Fiction?</i>
	Jeff Szer, Vic: (1445) <i>Cord Blood</i>	Stephen Henry, NZ: (1445) <i>Kodeocytes – Designer Red Cells Created with KODE™ Biosurface Engineering Technology</i>
	Ken Bradstock, NSW: (1505) <i>Haploidentical</i>	Damien Heathcote, Vic: (1505) <i>Use of Modified Red Cells as Diagnostic Tools</i>
1530-1600	AFTERNOON TEA (Exhibition Hall)	

PROGRAMME - Sunday 18 October 2009

0800–1900	Registration (Main Foyer)		
	Hall D	Hall A	Meeting Rooms 1/2
	ASTH	NURSES	BMTSAA
0900–1030	Symposium: Recent Developments in Haemostasis and Thrombosis	Symposium	Symposium: Regulation – Implementation & Impact
	Chair – Doug Coghlan	Chair – Bev Quested	Chairs - Annette Trickett/Nancy Messino
	Nigel Key, USA: (0900) <i>Tissue Factor – In Health and Disease</i>	Sherri Ozawa, USA: (0900) <i>Patient Blood Management</i>	Wendy Harris, NSW: (0900) <i>Regulation from the Auditor's Perspective</i>
	Paul Kyrle, Austria: (0945) <i>Update on the Protein C anticoagulation pathway</i>	Barbara Parker, SA: (0930) <i>Patient Blood Management in Australia: Where Are We Up to?</i>	Bev Wake, SA: (0920) <i>The Impact of Quality Management on a Collection Service</i>
		Annette Trickett, NSW: (0935) <i>NPAAC Guidelines and Requirements – Current Issues</i>	
	Discussion (1015)	Panel Discussion (1005)	
1030–1100	MORNING TEA (Exhibition Hall)		
1100–1200	Symposium: Current Controversies	Symposium: Extreme Haem-Haematology Nursing Out of the Metropolitan Area	Symposium: Post Transplantation Chimerism Analysis
	Chair – Ross Baker	Chair – Rosie Howard	Chair – Colin Story
	Claire McClintock, NZ: (1100) <i>Thrombophilia and Pregnancy Complications – To Test or Not To Test</i>	Julie Domanski, NT: (1100) <i>Transfusion in the Top End</i>	Judith Stevens, SA: (1100) <i>Chimerism Analysis and Methodology: The RAH Experience</i>
	Chris Ward, NSW: (1130) <i>To Bridge or Not to Bridge? – Managing Perioperative Anticoagulation</i>	Lisa Elliot, SA: (1130) <i>Assisting the Development of Outpatient Day Centre in India</i>	Tom Revesz, SA: (1120) <i>Chimerism and MRD Post-SCT in Children. A Guide to Immunotherapy in ALL?</i>
		Cheryl Hutchins, QLD: (1140) <i>Chimerism Analysis and GVHD</i>	
1200–1300	Barry Firkin Oration (Hall C)		
	Chair – Chris Ward		
	John Fletcher, NSW: Guidelines for Venous Thromboembolism Prophylaxis –Complexity, Confusion, Controversy		
1300–1400	LUNCH (Exhibition Hall)		
	ANZSBT AGM (Hall B) BMTSAA AGM (Meeting Rooms 1/2)		
1400–1530	Symposium: Anti-platelet Therapy and Arterial Thrombosis	Combined Session with HSANZ	Combined Session with HSANZ
	Chair – Tim Brighton		
	Huyen Tran, VIC: (1400) <i>Overview of Antiplatelet Therapy</i>		
	Marco Cattaneo, Italy : (1430) <i>Measuring Resistance to Anti-Platelet Drugs – Methods and Clinical Utility</i>		
1530-1600	AFTERNOON TEA (Exhibition Hall)		

PROGRAMME - Sunday 18 October 2009

	Hall C	Hall B
	HSANZ	ANZSBT
1600-1730	Symposium: Multiple Myeloma	ANZSBT/ASTH Combined Session: Critical Bleeding
	Chair - Andrew Spencer	Chair – James Isbister
	Thierry Facon, France: (1600) <i>A Guide for Clinicians on the New Therapies and How They Line Up Against Autologous Transplant</i>	Dafydd Thomas, UK: (1600) <i>Transfusion Medicine in Acute Bleeding</i>
	Andrew Spencer, VIC: (1645) <i>Australian Studies in Myeloma</i>	Lena Napolitano, USA: (1645) <i>Damage Control Resuscitation - Coagulopathy of Trauma</i>
	Andrew Zannettino, SA: (1710) <i>Pathophysiology of Bone Disease in Multiple Myeloma</i>	Benny Sorensen, UK: (1710) <i>The Role of Fibrinogen Concentrates in Managing Massive Transfusion</i>
1730-1930	Welcome Reception (Exhibition Hall)	

PROGRAMME - Sunday 18 October 2009

	Hall D	Hall A	Meeting Rooms 1/2
	ASTH	NURSES	BMTSAA
1600-1730	Nurses Free Communications 1: Apheresis	Nurses Free Communications 2: Discharge and Outpatient Care	Cell Therapy Infrastructure: Development and Subsidized Access
	Chair - Bev Wake	Chair - Moira Stephenson	Chair - Vinita Agarwal, NSW
	1600 O001 Grainne Dunne: <i>Troubleshooting the Way Through Therapeutic Plasma Exchange in a 2 year old boy with Thrombotic Thrombocytopenic Purpura (TTP)</i>	1600 O006 Trish Joyce: <i>The Development and Implementation of a Nurse-Led Follow-Up Clinic for Patients Who Have Undergone an Autologous Stem Cell Transplant (ASCT)</i>	Stewart Hay, VIC: (1600) <i>Cell Therapy Infrastructure: Development and Subsidized Access</i>
	1615 O002 Tracy Clarke: <i>Managing the Complexities of Renal Patients during Therapeutic Plasma Exchange</i>	1615 O007 Gillian Sheldon: <i>An Integrated Outpatient Autograft Program: The Royal Hobart Hospital Model of Care</i>	John Rasko, NSW: (1610) <i>Report from Australian Regional ISCT Meeting</i>
	1630 O003 Fran Owen: <i>Plasma Exchange for Treatment of Chronic Intractable Urticaria - a Single Case Experience</i>	1630 O008 Emily Russell, Annette Barnes, Kylie Hilford: <i>An Evaluation of a New Model Of Nursing Care in Queensland's Leading Haematology and Bone Marrow Transplant Unit</i>	Poster Discussion (1630) Hall E Chair – Judy Stevens
	1645 O004 Jennifer Leutenegger: <i>Use of the Fresenius COM.TEC Cell Separator for PBOC Collection: Ongoing Need for Apheresis Operator Interventions</i>	1645 O009 Kerrie Murphy: <i>Cancer Outreach Team: Taking the Hospital out of Myeloma</i>	
	1700 O005 Andrew Scullion: <i>Calcium Replacement in Apheresis</i>	1700 O010 Sandra Liddell: <i>The Haematology Step Down Unit - A Novel Approach to Early Discharge and the Continuity of Care Through Care Co-ordination</i>	
1730-1930	Welcome Reception (Exhibition Hall)		

PROGRAMME - Monday 19 October 2009

0700–1800	Registration (Main Foyer)	
	Hall C	Hall B
	HSANZ	ANZSBT
0715–0815	Masterclass Meeting Room 4 Chair – Daniel Owens Neal Young, USA: <i>Aplastic Anaemia/Aplastic AML</i>	
0830–1000	Free Communications 1 - 4 Free Communications 1: Hall C Chair – Andrew Wei Acute Leukaemia Abstracts #O011 – O016 Free Communications 2: Meeting Rooms 1/2 Chair – Peter Mollee Multiple Myeloma Abstracts #O017 – O022 Free Communications 3: Meeting Rooms 10/11 Chair – David Ritchie Supportive Care/Infectious Disease Abstracts #O023 – O028 Free Communications 4: Meeting Room 3 Chair – Lynda Campbell Advances in Diagnostic and Prognostic Markers Abstracts #O029 – O034 (See pages 56 - 57)	Presidential Symposium Chair – Dr Peter Flanagan 0830 O035 Zoe McQuilten <i>Transfusion is Associated with Adverse Clinical Outcomes in Cardiac Surgery: An Analysis of a Large Patient Cohort</i> 0845 O036 Jenny Morrison <i>Blood Group Molecular Typing - Complementing Serology to Manage Emerging Transfusion Needs in Clinical Practice</i> 0900 O037 Catherine Hyland <i>Duffy Typing on BLOOD-chip V1: Pilot Study to Classify Problematic Serology Samples</i> 0915 O038 John-Paul Tung <i>DNA Preliminary Findings from an Ovine Model of Blood Component Therapy Developed to Investigate Transfusion-Related Acute Lung Injury</i> 0930 O039 Melinda Dean <i>Mannose Binding Lectin Deficiency is Associated with Altered Myeloid Blood Dendritic Cell Function</i>
1000–1030	MORNING TEA (Exhibition Hall)	
1030–1130	HSANZ Nurses Combined Symposium: Transplantation 2 GvHD/GvL Chair – David Ma Sergio Giralt, USA: (1030) <i>GvL - Non-myceloablative Transplants</i> Geoff Hill, QLD: (1110) <i>The Control of Antigen Presentation by NKT Cell Activation After BMT</i>	Symposium: Managing the Blood Supply Chair – Ben Saxon Peter Flanagan, NZ: (1030) <i>Transfusion Transmitted Infection – An International Perspective</i> Robert Flower: (1050) <i>Transfusion-transmitted Infection – An Australian Perspective. Are We at Risk?</i> Meer-Taher Shabani-Rad, Canada: (1110) <i>Management of Blood Shortage in a Tertiary Hospital Setting – A Regional Canadian Model</i>
1130–1230	Carl de Gruchy Oration (Hall C) Chair - David Gottlieb Luen Bik To, SA: <i>The Planned and the Unexpected</i>	
1230–1330	LUNCH (Exhibition Hall)	
	ASTH AGM (Meeting Rooms 1/2) BMTSANZ AGM (Meeting Room 3) HSANZ Nurses Group AGM (Meeting Rooms 10/11)	

PROGRAMME - Monday 19 October 2009

0800–1900		Registration (Main Foyer)	
	Hall D	Hall A	
	ASTH	NURSES	
0830–1000	Free Communications 1	Free Communications 3: Patient Experiences & Perspectives	
	Chair – Claire McClintock	Chair – Barbara Parker	
	0830 Harshal Nandukar <i>GRP78 Exerts Novel Anti-thrombotic Activity and Localises to the Endothelium by Interacting with the Lectin-like Domain of Thrombomodulin</i>	O040	0830 Renee McMullen <i>Undergoing Peripheral Blood Stem Cell Collection: the Patients' Experience</i>
	0845 Huyen Tran <i>Thromboprophylaxis During Pregnancy – A Survey of Haematologists & Obstetricians</i>	O041	0845 Amy Munro <i>Upload, Download, Unload: LifeBloodLIVE - A New Zealand Online Forum for Haematology Patients</i>
	0900 Steven Lazar <i>Understanding Hospital Physicians Perspectives and Attitudes towards the Implementation of Venous Thrombosis Prophylaxis</i>	O042	0900 Priscilla Gates <i>The Development of a Haematology Late Effects Nurse Consultant Role with a National Scope</i>
	0915 Basia Diug <i>Risk Factors Contributing to High INR Results in Patients Receiving Warfarin Therapy in the Community</i>	O043	0915 Cassandra Reid <i>It's Just a Flesh Wound: Battling Hodgkins Lymphoma</i>
	0930 Huy Tran <i>Generation and Vitamin K Dependent Procoagulant Factors in Warfarinised Adult Patients</i>	O044	0930 Jacqueline Wykes <i>The Role of a Care Coordinator for Lymphoma Patients - Our Hospital's Initiative</i>
	0945 Simon McRae <i>Thrombin Generation in Inherited Protein S Deficiency</i>	O045	
1000–1030	MORNING TEA (Exhibition Hall)		
1030–1130	Symposium: Prevention and Treatment of Venous Thrombosis	Combined Session with HSNZ	
	Chair – Alex Gallus		
	John Eikelboom, Canada: (1030) <i>Recent Results from Trials of New Anticoagulants</i>		
	Harry Gibbs, QLD: (1110) <i>Venous Thromboembolism Prophylaxis Guideline Implementation</i>		
1130–1230	Carl de Gruchy Oration (Hall C) Chair - David Gottlieb Luen Bik To, SA: <i>The Planned and the Unexpected</i>		
1230–1330	LUNCH (Exhibition Hall) ASTH AGM (Meeting Rooms 1/2) BMTSANZ AGM (Meeting Room 3) HSANZ Nurses Group AGM (Meeting Rooms 10/11)		

PROGRAMME - Monday 19 October 2009

	Hall C	Hall B
	HSANZ	ANZSBT
1330–1500	Combined HSANZ/ASTH Presidential Symposium Chairs – David Gottlieb & Chris Ward 1330 O051 Susan Heatley <i>KIR Haplotype Influences Clinical Outcome Following HLA-Matched Sibling Haemopoietic Stem Cell Transplantation</i> 1345 O052 John EJ Rasko <i>Elasticity Preserves Primitive Murine and Human Haemopoietic Cells</i> 1400 O053 Sally Martin <i>CXCL12 Expression is Up-Regulated by Hypoxia in Multiple Myeloma Plasma Cells</i> 1415 O054 Campbell Tiley <i>Prevalence of Melanoma and Non-melanoma Skin Cancer in Chronic Lymphocytic Leukaemia in Australia</i> 1430 O055 Harshal Nandukar <i>Development of RSOLCD39-PSGL as a Novel Drug with Anti-thrombotic and Anti-inflammatory Effects</i> 1445 O056 Mohammad Al-Tamimi <i>Soluble Glycoprotein VI (GPVI) in Human Plasma: Shedding of GPVI from Platelets Induced by Coagulation</i>	Symposium Chair – David Roxby Paul Ness, USA: (1330) <i>Haemolytic Anaemia – Is There a Requirement for Urgent Transfusion?</i> Martin Olsson, Sweden: (1415) <i>New Developments in Immunohaematology</i>
1500-1530	AFTERNOON TEA (Exhibition Hall)	
1530-1630	Symposium: Lymphoma Chair - Mark Hertzberg Martin Dreyling, Germany: (1530) <i>Current Treatment Strategies in Mantle Cell Lymphoma</i>	Symposium: Blood Management Chair – TBC Bernd Froessler, SA: (1530) <i>Perioperative Blood Management</i> Kathryn Robinson, SA: (1550) <i>Iron Deficiency Anaemia: Preoperative Assessment</i> Erica Wood, VIC: (1610) <i>The Hidden Costs of Red Cell Transfusion</i>

PROGRAMME - Monday 19 October 2009

	Hall D	Hall A
	ASTH	NURSES
1330-1500	Combined Session with HSAZ	Symposium: Science Update
		Chair – Allan Hayward
		Narin Bak, SA: (1330) <i>Fungal Infections</i>
		Lyn Green & Mitra Guha, SA: (1415) <i>Management of Steroid Induced Hyperglycaemia</i>
1500-1530	AFTERNOON TEA (Exhibition Hall)	
1530-1630	Symposium: Inhibitor Management	Free Communications 4: Myeloma
	Chair – TBC	Chair - Cassi Sprague
	Nigel Key, USA: (1530) <i>Treating Patients with Inhibitors – Which Agent and How to Monitor</i>	1530 O057 Jacqueline Jagger <i>Moving on with Myeloma - A Novel Approach to Patient Support</i>
	Chris Barnes, VIC: (1610) <i>Inhibitors in Haemophilia – The Australian Perspective</i>	1545 O058 Tracy King <i>Quality and Equity in Myeloma Nursing Care: Development of Evidence Based Nursing Guidelines for the Management of Myeloma</i>
		1600 O059 Moir Stephens <i>Habitus: The Experiences of People Living With Myeloma</i>
		Free Communications 5: Clinical Practice
		Chair - Kristin Linke
		Meeting Room 1/2
		1530 O060 Kirstin Bubner <i>Telephone Triage - Implementation and Evaluation of a New System</i>
		1545 O061 Therese Graham <i>Human Immunodeficiency Virus (HIV) Lymphoma: an Overview of Disease and Treatment Regimens, a Review of the Literature</i>
		1600 O062 Tracy Clarke <i>Catheter Related Infections and Balancing Reality with Best Practice</i>

PROGRAMME - Monday 19 October 2009

	Hall C	Hall B
	HSANZ	ANZSBT
1630-1730	POSTERS (Rear of Exhibition Hall)	
1730-1830	<p>Masterclasses (HSANZ)</p> <p>Meeting Room 1/2 Chair – Andrew Wei 1 Alan Burnett, UK: <i>Which AML Patients to Transplant in CRI?</i></p> <p>Meeting Room 3 Chair – Geoff Hill 2 Sergio Giralt, USA: <i>Choosing the Optimal Conditioning Regimen for Each Patient - Are We There Yet?</i></p> <p>Meeting Room 10 Chair – Devendra Hiwase 3 Susan Branford, SA: <i>Mutation Testing and Quantitative BCR-ABL in Chronic Myeloid Leukaemia</i></p>	<p>Masterclasses (ANZSBT)</p> <p>Meeting Room 4 Chair – Cathy Hyland 4 Martin Olsson, Sweden: <i>Blood Group Genotyping – New Tools for Old Markers</i></p>

PROGRAMME - Monday 19 October 2009

	Hall D	Hall A
	ASTH	NURSES
1630-1730	POSTERS (Rear of Exhibition Hall)	
1730-1830	Masterclasses (ASTH) Meeting Room 5 Chair – Simon McRae 5 Nigel Key, USA <i>Inhibitor Management</i>	Masterclass (Nurses) Meeting Room 11 Chair – Bev Quested 6 Sherri Ozawa, USA <i>Nurse Led Clinics</i>

PROGRAMME - Monday 19 October 2009

Monday 19 October – 0830 – 1000

HSANZ Free Communications 1: Acute Leukaemia

Hall C

0830 **O011**
Amanda Hugman

Instability of FLT3 Mutations In Relapsed Acute Promyelocytic Leukemia (APL): A Comparative Analysis Of Paired Diagnostic And Relapse Bone Marrow Samples

0845 **O012**
Frank Firkin

Arsenic Pharmacodynamic Factors Impact on Efficacy of Treatment with Arsenic Trioxide in Combination with Idarubicin plus All-Trans Retinoic Acid for Acute Promyelocytic Leukaemia

0900 **O013**
Andrew Wei

Predictors of early mortality during ICE induction chemotherapy in adult AML: a sub-analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) AML M7 study

0915 **O014**
Andrew Wei

Elderly AML Patients (>60 years) with Poor Cytogenetic Features Treated with Investigational Agents have Superior Outcomes Compared to Those Receiving Intensive Chemotherapy

0930 **O015**
David S Ritchie

Clinical, Immunological and Haematopoietic Responses in a Phase-II Study of Lenalidomide (len) and Stem cell Factor (SCF) in Low IPSS Myelodysplastic Syndrome (MDS)

0945 **O016**
James X Gray

WT1 expression levels in bone marrow and peripheral blood of patients with acute myeloid leukaemia

Monday 19 October – 0830 – 1000

HSANZ Free Communications 2: Multiple Myeloma

Meeting Rooms 1/2

0830 **O017**
Hang Quach

High Dose Dexamethasone (dex) Counteracts the Immunostimulatory Effects of Lenalidomide (Len)

0845 **O018**
Andrew Spencer

Heat Shock Protein 90 Inhibitor Induces Apoptosis in Human Multiple Myeloma Cell Lines and Synergises with Azacytidine

0900 **O019**
YS Lee

Bortezomib may overcome adverse risk associated with increased tumor burden, but not metaphase-defined high risk cytogenetics

0915 **O020**
Peter Diamond

Elevated Serum Levels of CXCL12 is Associated with Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients

0930 **O021**
Terrence Diamond

Severity of Osteoporosis in Multiple Myeloma and the Prognostic Role of Lumbar Spine QCT

0945 **O022**
Sharon Williams

TWEAK Contributes to Osteolytic Disease in Multiple Myeloma Through the Induction of CXCL12

Monday 19 October – 0830 – 1000

HSANZ Free Communications 3: Supportive Care/Infectious Disease

Meeting Rooms 10/11

0830 **O023**
Anna Kalff

The Impact of Regular Erythrocytapheresis on Acute and Chronic Complications of Sickle Cell Disease in Adults

0845 **O024**
Biju George

Cytomegalovirus scoring index (CSI): A clinical score for predicting the likelihood of early cytomegalovirus reactivation following allogeneic stem cell transplantation

0900 **O025**
Emily Blyth

Adoptive immunotherapy for prophylaxis of cytomegalovirus infection in allogeneic haemopoietic stem cell transplant (HSCT) recipients – an update

0915 **O026**
Peter Mollee

Catheter-Related Bloodstream Infection Incidence And Risk Factors In Adults With Cancer: A Prospective Cohort Study

PROGRAMME - Monday 19 October 2009

0930 **O027**

Andrew Guirguis

Haemophagocytic Syndrome Associated With Tuberculosis – Early Recognition, Early Management

0945 **O028**

Patricia Walker

Development of a Protocol for Auditing Invasive Fungal Disease in High Risk Haematology and Stem Cell Transplantation Patients

Monday 19 October – 0830 – 1000

**HSANZ Free Communications 4:
Advances in Diagnostic and Prognostic Markers
Meeting Room 3**

0830 **O029**

Kate Burbury

Utility of flow cytometry (FC) in the assessment of therapeutic efficacy in myelodysplastic syndromes (MDS) treated with 5-azacitidine (AZA)

0845 **O030**

Andrew Lim

p53 immunohistochemistry (IHC) and high-resolution melting (HRM) analysis appears to aid classification, define adverse biology and improve sensitivity of residual disease detection in acute myeloid leukaemias (AML) with over 50% marrow erythroblasts

0900 **O031**

Peter Tan

Incidental Monoclonal Lymphocyte Populations in the Bone Marrow Assessed with Eight-Colour Diagnostic Flow Cytometry

0915 **O032**

Lindsay C Dunlop

Relationship Between the Single and Dual Platform CD34+ Cell Assays

0930 **O033**

Tina Noutsos

Implementation of a Northern Territory Wide Digital Microscopy System at Royal Darwin Hospital and Northern Territory Regional Hospitals for Blood Film Morphology Review

0945 **O034**

Amanda Hugman

MEG3 and DLK1 expression in patients with Acute Myeloid Leukemia (AML)

PROGRAMME - Tuesday 20 October 2009

0800–1800	Registration (Main Foyer)	
	Hall C	Hall B
	HSANZ	ANZSBT
0830–1000	Symposium: Acute Leukaemia/Leukaemia Biology	Free Communications 1
	Chair – Ian Lewis	Chair – Gina Aitken
	Daniel Tenen, USA: (0830) <i>Transcription Factor C/EBP alpha Regulates Hematopoietic Stem Cell Proliferation and Maintenance</i>	0830 O063 Louise Bobbitt <i>Efficacy of Prothrombinex®-VF for Acute Reversal of a Prolonged INR With or Without Fresh Frozen Plasma. A Two Centre Prospective Audit.</i>
	Alan Burnett, UK: (0915) <i>Insights from MRC Trials in AML</i>	0845 O064 Richard Charlewood <i>Benchmarking Transfusion Across New Zealand</i>
		0900 O065 Romi Sinha <i>Transfusion Practices in Massive Haemorrhage in Intensive Care</i>
		0915 O066 Louise Phillips <i>Understanding Transfusion Outcomes Through Clinical Registries: Validation of a Linkage Technique</i>
		0930 O067 Christopher Corkery <i>Appropriateness of Red Cell Usage within Seven Major New Zealand Hospitals</i>
		0945 O068 Romi Sinha <i>Snapshot of Current Platelet Transfusion Practice in Five South Australian Hospitals</i>
1000–1030	MORNING TEA (Exhibition Hall)	
1030–1130	Free Communications 5-8	Scientific Subcommittee & QAP Discussion
	Free Communications 5: Hall C Chair – Michael Harvey Chronic Lymphocytic Leukaemia Abstracts # O069 – O071	Chair – Peter Flanagan
	Free Communications 6: Meeting Rooms 1/2 Chair – John Rasko Haemopoietic and Mesenchymal Stem Cell Biology Abstracts # O073 – O076	Bronwyn Williams, QLD (1030)
	Free Communications 7: Meeting Rooms 10/11 Chair – Derk Hart (TBC) Immunotherapy Abstracts # O077 – O080	Scientific Subcommittee Reports (1100)
	Free Communications 8: Meeting Room 3 Chair – Noemi Horvath Plasma Cell Related Dyscrasias Abstracts # O081 – O084 (See page 62)	

PROGRAMME - Tuesday 20 October 2009

0800–1800		Registration (Main Foyer)	
	Hall D	Hall A	
	ASTH	NURSES	
0830–1000	Symposium: Topics in Venous Thrombosis	Symposium: Recovery, Survivorship, and Adolescents	
	Chair – Chris Ward	Chair – Deb Hayes	
	Paul Kyrle, Austria: (0830) <i>Diagnosis of Venous Thrombosis</i>	Morgan Atkinson, SA: (0830) <i>Exercise and Recovery from Cancer: From Research to Clinical Practice</i>	
	Andrew Lee, SA: (0910) <i>Cerebral Venous Sinus Thrombosis: An Update</i>	Sharon Bowering, SA: (0900) <i>Adolescent and Young Adult Issues for Cancer Care</i>	
Kurosh Parsi, NSW: (0935) <i>Post-thrombotic Syndrome- Diagnosis, Prevention and Management</i>	Alison Keenan, SA: (0930) <i>A Survivorship Programme in South Australia</i>		
1000–1030	MORNING TEA (Exhibition Hall)		
1030–1130	ASTH Free Communications 2	Symposium: Consent in Blood Transfusion	
	Chair – Joanne Joseph	Chair – Lisa Stevenson	
	1030 O085 Chee Wee Tan <i>Lepirudin Use and Laboratory Monitoring in Patients on Chronic Haemodialysis with a History of Heparin-induced Thrombocytopenia(HIT)</i>	Kathryn Robinson, SA & Russell Hunt, SA: (1030) <i>Consent in Blood Transfusion Symposium – ANZSBT Survey</i>	
	1045 O086 Huy Tran <i>Heparin-induced Thrombocytopenia (HIT): Evaluation of Soluble Platelet Glycoprotein VI as a Biomarker for HIT</i>	Shannon Farmer, WA: (1100) <i>A Patient's Perspective – The Patient from Hell</i>	
	1100 O087 Marie-Christine Morel Kopp <i>Rapid Diagnosis of Heparin-Induced Thrombocytopenia by Whole Blood Impedance Aggregometry</i>		
	1115 O088 Marie-Christine Morel-Kopp <i>Heparin-induced Thrombocytopenia: Evaluation of ELISA Assays</i>		

PROGRAMME - Tuesday 20 October 2009

	Hall C	Hall B
	HSANZ	ANZSBT
1130–1230	Ruth Sanger Oration (Hall B) Chair - Dr Peter Flanagan Albert Farrugia, USA: <i>Falsifiability of Component Therapy – Karl Popper, Thomas Kuhn and the Common Sense of Transfusion Medicine</i>	
1230–1330	LUNCH (Exhibition Hall) HSANZ AGM (Meeting Rooms 1/2)	
1330–1500	Symposium: Risk Adapted Therapy Chair – Andrew Roberts Thierry Facon, France: (1330) <i>Myeloma</i> Martin Dreyling, Germany: (1400) <i>Lymphoma</i> Tim Hughes, SA: (1430) <i>Monitoring Response in Chronic Myeloid Leukaemia</i>	ANZSBT Nurses Combined Symposium: Blood Management Co-chairs – Erica Wood & Bev Quested Dafydd Thomas, UK: (1330) <i>Do Transfusion Guidelines Reduce Transfusion Requirements?</i> Rachel Whitford, SA: (1400) <i>Where Does All Our Blood Go?</i> Sherri Ozawa, USA: (1430) <i>Developing a Blood Management Program</i>
1500-1530	AFTERNOON TEA (Exhibition Hall)	
1530-1630	Symposium: Drug Approval Chair – David Gottlieb Andrew Roberts, VIC: (1530) <i>Access to New and High Cost Drugs in Australia - Some Insights</i> Peter Browett, New Zealand: (1550) <i>New Zealand Experience</i> Kevin Lynch: (1610) <i>Challenges to New Drug Development and Approval: Experience and Opinion of an Industry Medical Director</i>	Symposium: IVIg – Have We Got it Right? Chair – Ellen Maxwell Alison Turner, ACT: (1530) <i>A National Overview</i> Marija Borosak, VIC: (1550) <i>A View From The Australian Red Cross Blood Service</i> Robert Heddle, SA: (1610) <i>A Clinician's Perspective</i>
1630-1730	Masterclasses (HSANZ) Meeting Rooms 1/2 Chair – Laurie Catley 7 Thierry Facon, France: <i>Myeloma – From Genetic Abnormalities to Targeted Therapy</i> Meeting Room 3 Chair – Humphrey Pullon 8 Martin Dreyling, Germany: <i>Waldrenstrom Macroglobulinaemia – What's New?</i>	Masterclasses (ANZSBT) Meeting Room 4 Chair – Richard Charlewood 10 Paul Ness, USA: <i>Haemodilution – The Role in Transfusion Practice</i> Meeting Room 5 Chair – Susan Ireland 11 Meer-Taher Shabani-Rad, Canada: <i>Preparation and Implementation of a Practical Hospital Based Blood Shortage Contingency Plan</i>
1900	CONFERENCE DINNER	

PROGRAMME - Tuesday 20 October 2009

	Hall D	Hall A	
	ASTH	NURSES	
1130–1230	Ruth Sanger Oration (Hall B) Chair - Dr Peter Flanagan Albert Farrugia, USA: <i>Falsifiability of Component Therapy – Karl Popper, Thomas Kuhn and the Common Sense of Transfusion Medicine</i>		
1230–1330	LUNCH (Exhibition Hall) HSANZ AGM (Meeting Rooms 1/2)		
1330–1500	Symposium: Rare Bleeding Disorders Chair – Mark Smith	Combined Symposium with ANZSBT	QAP-Morphology: Interactive Case Presentations Hall A Co-chairs: Katherine Marsden & Surender Juneja
	Marco Cattaneo, Italy: (1330) <i>Platelet Function Disorders – Mechanism and Diagnosis</i>		Speakers : Katherine Marsden, VIC Surender Juneja, VIC David Westerman, VIC Chris Barnes, VIC
	Elizabeth Duncan, SA: (1410) <i>Factor XIII Deficiency</i>		
	Simon McRae, SA: (1435) <i>Paraproteinemia and Coagulation Disorders</i>		
1500-1530	AFTERNOON TEA (Exhibition Hall)		
1530-1630	Symposium: New Risk Factors for Thrombosis Chair – TBC	Free Communications 6: Transfusion Chair – Anne Canty	
	Natalie Pecheniuk, QLD: (1530) <i>The Good and the Bad - Plasma Lipoproteins in Coagulation and Venous Thrombosis</i>	1530 O089 Emily Allen <i>Changing Model of Care - The Role of the Blood Transfusion Clinical Nurse Consultant</i>	
	Ross Baker WA: (1600) <i>Stroke, Thrombotic Thrombocytopenic Purpura and ADAMTS13 Activity</i>	1545 O090 Charlene Mclaren <i>Collaborative Nurse Led Tranfusion Clinic - 18 Months On!</i>	
		1600 O091 Emily Allen <i>Influencing Factors on Chelation Compliance in Transfusion Dependant Haemoglobinopathy Patients</i>	
		1615 O092 Linley Bielby <i>So You Think Giving a Blood Transfusion is Easy!</i>	
1630-1730	Masterclasses (ASTH) Meeting Room 11 Chair – Chris Ward 12 Paul Kyrie, Austria: <i>Managing Patients with Venous Thrombosis</i>		
1900	CONFERENCE DINNER		

PROGRAMME - Tuesday 20 October 2009

Tuesday 20 October – 1030-1130

HSANZ Free Communications 5: Lymphocytic Leukaemia

Hall C

1030 **O069**
Robert Weinkove

Invariant Natural Killer T Cells in Chronic Lymphocytic Leukaemia

1045 **O070**
Chelsee Hewitt C

Mutation Screening of TP53 Exons 2-11 in Chronic Lymphocytic Leukaemia Using High Resolution Melting Analysis

1100 **O071**
Melinda Burgess

CCL2, CXCL2, IL-6 and IL-8 are Expressed in Primary Chronic Lymphocytic Leukaemia Cell Cultures and Enhance CLL Cell Long-Term Survival in vitro

Tuesday 20 October – 1030-1130

HSANZ Free Communications 6: Haemopoietic and Mesenchymal Stem Cell Biology Meeting Rooms 1/2

1030 **O073**
Robert Welschinger

Temporal Differences in Mobilisation of Normal and Malignant Hematopoietic Cells by the CXCR4 Antagonist AMD3100

1045 **O074**
Jason Powell

*Late Breaking Abstract:
Osteopontin expression levels are a prognostic indicator of overall patient survival in cytogenetically normal acute myeloid leukaemia*

1100 **O075**
Anna Brown

The GM-CSF Receptor Utilises beta-catenin and TCF4 to Specify Macrophage Lineage Differentiation

1115 **O076**
Lawrence Jyh Yeu Liew

Characteristics of Bone Marrow Derived Mesenchymal Stromal Cells in Myelodysplasia

Tuesday 20 October – 1030-1130

HSANZ Free Communications 7: Immunotherapy Meeting Rooms 10/11

1030 **O077**
Frank Vari

EBV-specific T cells as Therapy for Relapsed / Refractory EBV-Positive Lymphomas

1045 **O078**
Emily Blyth

Epstein-Barr Virus specific cytotoxic T cells for clinical use in immune reconstitution post haemopoietic stem cell transplant

1100 **O079**
Leighton Clancy

Comparison of Cytomegalovirus (CMV) pp65 Specific T Cell Generation from Mobilised Peripheral Blood Stem Cell (PBSC) Collections and Whole Blood

1115 **O080**
Derek Hart

Developing a Therapeutic Anti - Dendritic Cell Antibody to Prevent GVHD

Tuesday 20 October – 1030-1130

HSANZ Free Communications 8: Plasma Cell Related Dyscrasias Meeting Room 3

1030 **O081**
Peter Mollee

Determinants of Survival In Australian Patients With AL Amyloidosis

1045 **O082**
Sant-Rayn Pasricha

Bone Marrow Plasma Cells at Diagnosis of Waldenstrom's Macroglobulinemia

1100 **O083**
Peter Mollee

Borderline High Serum Free Light Chain (FLC) Kappa:Lambda Ratios Are Seen Not Only In Dialysis Patients, But Also In Non-Dialysis Dependent Renal Impairment And Inflammatory States

1115 **O084**
Terry Golombick

The Potential Role of Curcumin (diferuloylmethane)in Patients with MGUS [Monoclonal Gammopathy of Undetermined Significance]

PROGRAMME - Wednesday 21 October 2009

0800–1300	Registration (Main Foyer)	
	Hall C	Hall B
	HSANZ	ANZSBT
0830–1000	Symposium: Targeted Therapy	Free Communications 2
	Chair – Tim Hughes	Chair – Simon Benson
	Daniel Tenen, USA: (1100) <i>Acute Leukaemia</i>	0830 O093 Jennifer Condon <i>An Age-dependent ABO Discrepancy Between Mother and Baby Reveals a Novel Aweak Allele</i>
	Radek Skoda, Switzerland: (1130) <i>JAK2 Mutation Positive Myeloproliferative Diseases</i>	0845 O094 Neil Waters <i>PUPPY Underpins Platelet Planning: Results from the Prospective Utilisation of Platelets and Plasma (Puppy) Study</i>
	Junia Melo, SA: (1200) <i>Molecular Targeted Therapy of CML</i>	0900 O095 Marija Borosak <i>Bacterial Screening of Platelets in Australia: First 12 Month Experience</i>
		0915 O096 Ken Nollet <i>Combined Prion and Leukocyte (PR*LR) Filters Vary with Respect to Vesicle Formation During Storage</i>
		0930 O097 Mary Comande <i>FPP Puppy Digs Up Some Surprising Results - Prospective Utilisation of Platelets and Plasma (Puppy) Study</i>
		0945 O098 Zane Kaplan <i>Routine Autologous Blood Collection and Subsequent Transfusion for Donors of Bone Marrow (BM) is Unnecessary</i>
1000–1100	MORNING TEA (Exhibition Hall)	
1100–1230	Free Communications 9 - 12	ANZSBT ASTH Combined Symposium: Anti-thrombotics and Anti-platelets: Problems They Cause
		Co-chairs – Simon McRae & TBC
	Free Communications 9: Hall C Chair – Geoff Hill Stem Cell Transplantation Abstracts #O111 – O116	Kate Burbury, VIC: (1100) <i>Reversal of Anticoagulants: Old and New. The Emerging Paradigm</i>
	Free Communications 10: Meeting Rooms 1/2 Chair – Peter Bardy Lymphoma Abstracts #O117 – O121	Lena Napolitano, USA: (1130) <i>Heparin-induced Thrombocytopenia in the Critical Setting</i>
	Free Communications 11: Meeting Rooms 10/11 Chair – Deb White Chronic Myeloid Leukaemia Abstracts #O123 – O128	Benny Sorensen, UK: (1200) <i>Novel Tests for Monitoring Haemostasis and Anticoagulants</i>
	Free Communications 12: Meeting Room 3 Chair – Richard D'Andrea Leukaemia Biology Abstracts #O129 – O134	
	(See pages 66 - 67)	

PROGRAMME - Wednesday 21 October 2009

0800–1800		Registration (Main Foyer)	
	Hall D	Hall A	
	ANZSBT	ASTH	
0830–1000	Free Communications 3	Free Communications 3	
	Chair – David Irving	Chair – Ram Suppiah	
	0830 Susanta Ghosh <i>Haemovigilance In New Zealand – Four Years & Counting ...</i>	O099	0830 Elizabeth Duncan <i>Patients with Enhanced Clot Solubility in Acid Conditions Require Differentiation between Raised Plasma Levels of the Aspartic Protease Pepsinogen I and Inhibitory Antibodies to Factor XIII</i>
	0845 Zoe McQuilten <i>Hospital Influences Risk of Transfusion in Cardiac Surgery: An Analysis of a Large Patient Cohort</i>	O100	0845 Sue Rodgers <i>Exon 28 Mutation Testing in von Willebrand Disorder</i>
	0900 Louise Bobbit <i>An Audit of the Safety and Efficacy of Prothrombinex®-VF for Acute Reversal of a Prolonged INR, at Two Large City Hospitals</i>	O101	0900 Lay Tay <i>Gestational Thrombocytopenia in Three Sisters with Type 2B von Willebrand's Disorder</i>
	0915 Joanne Main <i>How is a Tool Developed for the Aerospace Industry being used to Prevent a Leading Cause of ABO Incompatible Transfusions?</i>	O102	0915 Natalie Tjen <i>Vancomycin Induced Thrombocytopenia In Hospitalised Patients</i>
	0930 Rachel Donegan <i>Bedside Transfusion Practice Audit .An Audit in Eight New Zealand Hospitals</i>	O103	0930 Sant-Ryan Pasricha <i>Is Bone Marrow Examination Necessary to Safely Manage Idiopathic Thrombocytopenic Purpura in Adults?</i>
	0945 Lisa Stevenson <i>Procedural Adverse Events in Transfusion – Lessons from STIR 2006-09</i>	O104	0945 Andrew Guirguis <i>Antiphospholoid Testing: Is More Necessarily Better?</i>
1000–1100	MORNING TEA (Exhibition Hall)		
1100–1230	RACP Supervisors Workshop (Mtg Room 3)		

PROGRAMME - Wednesday 21 October 2009

Wednesday 21 October – 1100-1230

HSANZ Free Communications 9: Stem Cell Transplantation

Hall C

1100 O111

Elango Subramonia Pillai

Prognostic impact of elevated pre-transplant serum ferritin in patients undergoing allogeneic haemopoietic stem-cell transplantation for AML

1115 O112

Mary Sartor

Increased Expression of the Chemokine Receptor CCR5 on Human Blood Dendritic Cells is Associated with Acute Graft vs Host Disease post Allogeneic Stem Cell Transplantation

1130 O113

Adam Bryant

Fludarabine/Melphalan Allografting in Australia and New Zealand, 1998-2008: Excellent overall survival in a high-risk population

1145 O114

Nalini Pati

Factors predicting the outcome of the blood and marrow transplant patients admitted to Intensive Care Unit

1200 O115

Dejan Radeski

The Impact Of An Outpatient Based Autologous Stem Cell Transplant Service (ASCT) On Hospital Bed Stay And Clinical Resources. The Sir Charles Gairdner Hospital Experience

1215 O116

Biju George

Haplo-identical transplant without T cell depletion using a reduced intensity conditioning protocol in feasible in older patients with haematological malignancies

Wednesday 21 October – 1100-1230

HSANZ Free Communications 10: Lymphoma

Meeting Rooms 1/2

1100 O117

Kirsten E Herbert

Long-Term Outcomes of 90 Patients with Primary Cutaneous B-Cell Lymphoma: Analysis of the Peter MacCallum Cancer Centre/ St Vincent's Hospital Melbourne Cutaneous Lymphoma Database

1115 O118

Rebecca Howman

Hyper-CVAD + Rituximab followed by high-dose busulfan, melphalan and autologous stem cell transplantation in first response is well-tolerated and produces prolonged event free survival in patients with mantle cell lymphoma (MCL)

1130 O119

Kritika Chaiwatanatorn

Protein Kinase C beta II Expression In Diffuse Large B Cell Lymphoma Predicts For Inferior Outcome Of Anthracycline Based Chemotherapy With And Without Rituximab

1145 O120

Sung Kai Chiu

Retrospective analysis of patients with primary CNS lymphoma treated with methotrexate and reduced dose whole-brain radiotherapy

1200 O121

Uwe Hahn

Cardiovascular Disease Is A Frequent Late Complication In Survivors Of Hodgkin Lymphoma

Wednesday 21 October – 1100-1230

HSANZ Free Communications 11: Chronic Myeloid Leukaemia Meeting Rooms 10/11

1100 O123

Kate Vandyke

The tyrosine kinase inhibitor dasatinib dysregulates bone remodelling through inhibition of osteoclasts in vivo

1115 O124

Amity Frede

Enhancing the Functional Activity of the OCT-1 Influx Pump in De-novo CML Patients May Greatly Improve Response to Imatinib

1130 O125

Devendra K Hiwase

Short-Term Intense Bcr-Abl Kinase Inhibition is Adequate to Trigger Cell Death in CML-CD34+ Cells But Only if They are Simultaneously Cytokine Deprived

1145 O126

Jane Engler

OCT-1 Activity in CML CD34+ Cells is Not Predictive of Molecular Response to Imatinib Treatment in CP-CML Patients

1200 O127

Jane Wylie

A Population-Based Study of Responses to Imatinib in the Treatment of Newly Diagnosed Patients with Chronic Myeloid Leukaemia in New Zealand

1215 O128

Verity Saunders

OCT-1 SNPs known to reduce function do not account for the observed interpatient variability in OCT-1 Activity or response to imatinib in the Australian TIDEL trial

PROGRAMME - Wednesday 21 October 2009

Wednesday 21 October – 1100-1230

HSANZ Free Communications 12:

Leukaemia Biology

Meeting Room 3

1100 **O129**

Sonya Diakiw

A Role for Klf5 as a Tumour Suppressor in AML

1115 **O130**

Daniel Thomas

New targets for the protein kinase activity of PI3K: implications for deregulated cell survival in acute myeloid leukaemia

1130 **O131**

Michelle Perugini

Repression of Gadd45a by Activated FLT3 Receptors and DNA Methylation in AML

1145 **O132**

William Stevenson

Membrane bound phosphatase genes are epigenetically regulated in Acute Lymphoblastic Leukemia

1200 **O133**

Christina Brown

A Distinct Set of MicroRNAs Differentiates Acute Promyelocytic Leukaemia According to FLT3 Mutation Status

1215 **O134**

Christina Brown

Up-regulated Expression of a Large MicroRNA Gene Cluster in Acute Promyelocytic Leukaemia